Please assess the completion status of the following clinical trial:

Trial Title: Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion criteria:~1. Chronic hepatitis C genotype 1 infection, diagnosed at least 6 months prior to screening~2. Treatment naive or confirmed prior treatment relapse or partial response following treatment with interferon and ribavirin~3. Age 18 to 70 years~4. HCV RNA (Hepatitis C Virus RiboNucleic Acid) = 1,000 IU/mL at screening~5. Liver biopsy or fibroscan to exclude cirrhosis~Exclusion criteria:~1. Hepatitis C Virus (HCV) infection of mixed genotype; Hepatitis B Virus (HBV) or Human Immunodeficiency Virus (HIV) co-infection~2. Evidence of acute or chronic liver disease due to causes other than chronic HCV infection,~3. Decompensated liver disease, or history of decompensated liver disease,~4. Body weight \< 40 or \> 125 kg,~5. Clinical evidence of significant or unstable cardiovascular disease, chronic pulmonary disease, history or evidence of retinopathy or clinically significant ophthalmological disorder~6. Pre-existing psychiatric condition that could interfere with the subject's participation in and completion of the study~7. Laboratory parameters disorders (thalassemia major, sickle cell anemia or glucose 6 phosphate dehydrogenase deficit)~8. Hemoglobin \< 12 g/dL for women and \< 13 g/dL for men~9. Patients who have been previously treated with at least one dose of any antiviral or immunomodulatory drug other than interferon alfa or ribavirin for acute or chronic HCV infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): Effect of BI 207127 on BI 201335, the effect of BI 201335 and dual oral direct acting antiviral (DAAs) on caffeine, tolbutamide and midazolam
- Group B (Type: EXPERIMENTAL): Effect of BI 201335 on BI 207127, the effect of BI 207127 and metabolites and dual oral DAAs on caffeine, tolbutamide and midazolam
- Group C (Type: EXPERIMENTAL): Effect of Dual oral DAAs on tenofovir
- Group D (Type: EXPERIMENTAL): Effect of BI 201335 and BI 207127 at 600 mg b.i.d. on caffeine, tolbutamide and midazolam
- Group E (Type: EXPERIMENTAL): Effect of BI 201335 and BI 207127 on raltegravir

Based on this trial design, predict the completion outcome and termination type (if applicable).